There’s not a great deal of price action being seen in Friday’s early trade, but SkinBioTherapeutics is back on the radar again. A week ago the CEO resigned following accounting issues coming to light and today the company announced that it had engaged forensic auditors in a bid to understand the full extent of the situation. That’s necessary because the management team want to get interim results published, but it all comes at a price. The SkinBioTherapeutics share price fell a further 7% in early trade, taking cumulative losses from this event to almost 75%.
Maybe a slightly underwhelming market response to full year results published by the warehouse to data centre operator Segro this morning, but the company headlined with news of a 6% growth in like for like rental income, occupancy rates up 90 bps to 94.9% and a 6% uptick in dividends. Management also noted the business as being primed for further growth but with no real surprises her ethe share price was broadly unchanged approaching 9am.
The £160m rare gas specialists Pulsar issued an update this morning following news of a funding round. £7.4m was raised to accelerate development and commence drilling at two separate sites in the US. Shares were offered at 80p, but shortly after the open the underlying was trading at 82p and whilst that’s only a modest premium to the new issue price, it’s heading in the right direction so ought to convey some confidence. The Pulsar Helium share price was 12% lower shortly after the open.
Most read news on Investegate this morning
Trading Statement - - Tullow Oil (TLW)
Results for the year ended 31 December 2025 - - SEGRO (SGRO)
Anglo American full year 2025 Results - - Anglo American (AAL)
